Meanwhile, two phase 3 studies focusing specifically on weight management with orforglipron, ATTAIN-1 and ATTAIN-2, are also due to generate results in the third quarter of 2025, setting up a possible filing for obesity before the end of the year
We just have to watch you a little closer to make sure your pressure doesnt get too low as the weight falls off
This flexibility allows you to fit your injections into your routine
For example, in a 48-week trial, retatrutide induced body weight reductions of ~24% in some groups
BMC Medicine, 18 (1), 248
The class action complaint pointed to a lack of clinical data that supports the notion that simply boosting the amount of naturally occurring GLP-1 in the body has sustained weight-loss effects. In the era of GLP-1 agonist medications, what can supplement companies say about products that claim to support the drugs